中国晚期乳腺癌临床诊疗专家共识2016 被引量：75

导出

摘要晚期乳腺癌（ABC）患者在治疗方案的选择以及疗效方面是有其特殊性的，并且目前尚缺乏公认的标准治疗方案，如何帮助患者做出正确的治疗选择，是每一位肿瘤科医师面临的挑战。晚期乳腺癌患者的总体中位生存期为2～3年，不同分子亚型的情况有所不同。对于人类表皮生长因子受体2（HER2）阳性晚期乳腺癌患者，抗HER2治疗改变了HER2阳性乳腺癌的自然病程，

作者徐兵河江泽飞胡夕春

机构地区中国医学科学院肿瘤医院内科

出处《中华医学杂志》 CAS CSCD 北大核心 2016年第22期1719-1727,共9页 National Medical Journal of China

关键词晚期乳腺癌临床诊疗人类表皮生长因子受体标准治疗方案乳腺癌患者专家中国 HER2

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献48

1Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in1038 women with metastatic breast cancer[ J]. Ann Oncol,2008,19: 2012-2019.
2Theodoros F, Tommy F, Tobias L, et al. Age-specific trends ofsurvival in metastatic breast cancer : 26 years longitudinal datafrom a population-based cancer registry in Stockholm, Sweden[J]. Breast Cancer Res Treat, 2011.
3Chen W, Zheng R,Baade PD, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016, 66(2) : 115-132.
4Gonzalez-Angulo Am, Morales-Yasquez F, Hortobagyi GN.Overview of resistance to systemic therapy in patients with breastcancer [ J ]. Adv Exp Med Biol,2007,608 ; 1 -22.
5Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDGPET on defining the extent of disease and on the treatment ofpatients with recurrent or metastatic breast cancer[ J]. AJR Am JRoentgenol, 2004,183(2) :479-486.
6Arslan C , Sari E, Aksoy S,et al. Variation in hormone receptorand HER-2 status between primary and metastatic breast cancer :review of the literature[ J]. Expert Opin Ther Targets,2011, 15(1): 21-30.
7Neuman HB, Morrogh M, Gonen M, et al. Stage IV breast cancerin the era of targeted therapy: does surgery of the primary tumormatter[J]. Cancer,2010,116(5) : 1226-1233. DOI: 10.1002/cncr. 24873.
8Hortobagyi GN. Multidisciplinary management of advancedprimary and metastatic breast cancer [ J ]. Cancer, 1994, 74 ( 1Suppl) : 416-423.
9Sinacki M, Badzio A, Welnicka-Ja^kiewicz M, et al. Pattern ofcare in locally advanced breast cancer : focus on local therapy [ J ].The Breast, 2011 , 20 ( 2) : 145-150. DOI; 10. 1016/j. breast.2010.08.008.
10Cardoso F, Costa A, Norton L, et al. 1 st International consensusguidelines for advanced breast cancer ( ABC 1 ) [ J]. The Breast,2012,21(3) : 242-252. DOI: 10. 1016/j. breast. 2012.03. 003.

二级参考文献11

1Kao KJ, Chang KM, Hsu HC, et al. Correlation of microan'ay-based breast cancer molecular subtypes and clinical outcomes : implications for treatment optimization. BMC Cancer, 2011, 11 : 143.
2Fernendez Y, Cueva J, Palomo AG, et al. Novel therapeutic approaches to the tmatnent of metastatic breast cancer. Cancer Treat Rev, 2010, 36:33-42.
3Fumoleau P, Largillier R, Clippe C, et al. Muhicentre, phase U study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer, 2004, 40:536-542.
4Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase Ⅱ study of oral eapecitabine ( Xeloda ) in patients with metastatic breast cancer relapsing after treatment with a taxane- containing therapy. Ann Oncol, 2003, 14:1227- 1233.
5Malmstrom A, Hansen J, Malmberg L, et al. Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: a phase Ⅱ study. Acta Oncol, 2010, 49:35-41.
6O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus deeetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase m trial results. J Clin Oncol, 2002, 20:2812-2823.
7Blum JL, Dees EC, Vukelja SJ, et al. Phase Ⅱ trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer, 2007, 7:465-470.
8Chan A, Verrill M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer, 2009, 45:2253-2265.
9Ciruelos EM, Cortes J, Cort6s-Funes H, et al. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase Ⅱ study ( SOLTI 0301 trial). Ann Oncol, 2010, 21 : 1442-1447.
10Liu G, Franssen E, Fitch M, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol, 1997, 15:110-115.